Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : ElevateBio
Deal Size : Undisclosed
Deal Type : Collaboration
Xcell Collaborates with ElevateBio to Advance C&G Therapies Technology Development
Details : The collaboration aims to explore novel approaches to improve therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR incubator system for cell therapy research and development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : ElevateBio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AmplifyBio
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Xcell Biosciences Expands AmplifyBio Partnership For Cell and Gene Therapies
Details : The collaboration aims to identify key elements for successful manufacture of TCR therapies. Experiments have progressed from in vitro to in vivo, to target human papillomavirus-positive tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AmplifyBio
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Casdin Capital
Deal Size : $27.5 million
Deal Type : Series B Financing
Xcellbio Announces $27.5 Million Series B Financing
Details : Proceeds will support the company’s continued growth as a pioneer in built-to-purpose technology platforms for the development and manufacturing of cell and gene-based therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Casdin Capital
Deal Size : $27.5 million
Deal Type : Series B Financing